Para pesquisar informação científica, deverá especificar pelo menos dois termos de pesquisa
Search Medical Information
April 06 - 08, 2024
PDF
Soluble suppression of tumorigenicity 2 (sST2) and cardiovascular outcomes in persons with type 2 diabetes randomized to dapagliflozin vs Placebo - Analysis from the DECLARE-TIMI 58 trial
pdf
The effect of dapagliflozin on days of full health lost due to death, hospitalization, and impaired well-being in DAPA-HF
Dapagliflozin in patients with heart failure across a range of left ventricular hypertrophy in the DELIVER trial
SGLT2 inhibitors and major adverse cardiovascular events in patients with diabetes at high risk for atherosclerotic cardiovascular disease, heart failure or chronic kidney disease: A SMART-C collaborative meta-analysis
Cause-specific healthcare costs following hospitalization for heart failure with reduced vs mildly reduced/preserved ejection fraction
Mortality and cardiovascular outcomes in patients with heart failure and chronic kidney disease with recurrent hyperkalemia: REVOLUTIONIZE III study
Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalemia episode among patients with heart failure: A multi-country, cohort study
Geographical and treatment variations in patients with transthyretin cardiomyopathy in the Medicare fee-for-service population
Não encontra o que procura?
Contacte-nos
Encontre um Medical Healthcare Partner
Submeter uma questão